| Biological Sciences | Lifetime | 227 | NL 5 | 99.97 |
| Biological Sciences | 2021-2025 | 89 | NL 2 | 99.92 |
| Immunology | Lifetime | 14 | NL 1 | 99.97 |
| Infectious Diseases | Lifetime | 27 | NL 2 | 99.89 |
| Epidemiology | Lifetime | 225 | NL 4 | 99.71 |
| Genetics | Lifetime | 702 | NL 16 | 98.30 |
| Microbiology | Lifetime | 382 | NL 19 | 92.52 |
| Parasitology | Lifetime | 707 | NL 13 | 82.91 |
| Immunology | 2021-2025 | 1 | NL 1 | 99.94 |
| Infectious Diseases | 2021-2025 | 104 | NL 2 | 98.34 |
| Epidemiology | 2021-2025 | 352 | NL 6 | 97.18 |
| Genetics | 2021-2025 | 154 | NL 5 | 95.84 |
| Molecular Biology | 2021-2025 | 841 | NL 12 | 95.34 |
| COVID-19 Impact on Reproduction | Lifetime | 1 | NL 1 | 99.94 |
| Immune Response and Inflammation | Lifetime | 7 | NL 1 | 99.97 |
| Antifungal resistance and susceptibility | Lifetime | 8 | NL 1 | 99.90 |
| Immune responses and vaccinations | Lifetime | 1 | NL 1 | 99.96 |
| Immune cells in cancer | Lifetime | 13 | NL 2 | 99.88 |
| Inflammasome and immune disorders | Lifetime | 7 | NL 1 | 99.91 |
| Vaccine Coverage and Hesitancy | Lifetime | 13 | NL 1 | 99.71 |
| COVID-19 Clinical Research Studies | Lifetime | 41 | NL 2 | 99.69 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 33 | NL 1 | 99.76 |
| Fungal Infections and Studies | Lifetime | 20 | NL 4 | 99.80 |
| Diabetes and associated disorders | Lifetime | 44 | NL 1 | 99.62 |
| Inflammation biomarkers and pathways | Lifetime | 7 | NL 3 | 98.96 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 51 | NL 3 | 99.33 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 103 | NL 1 | 99.40 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 244 | NL 12 | 99.03 |
| Immune Cell Function and Interaction | Lifetime | 472 | NL 13 | 99.37 |
| Long-Term Effects of COVID-19 | Lifetime | 214 | NL 7 | 98.02 |
| interferon and immune responses | Lifetime | 169 | NL 1 | 98.78 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 178 | NL 5 | 98.83 |
| Sepsis Diagnosis and Treatment | Lifetime | 249 | NL 10 | 98.85 |
| Pediatric health and respiratory diseases | Lifetime | 207 | NL 8 | 98.51 |
| IL-33, ST2, and ILC Pathways | Lifetime | 140 | NL 3 | 98.60 |
| Antimicrobial Peptides and Activities | Lifetime | 253 | NL 11 | 97.67 |
| Neonatal Respiratory Health Research | Lifetime | 701 | NL 26 | 98.25 |
| Tuberculosis Research and Epidemiology | Lifetime | 547 | NL 16 | 98.11 |
| Epigenetics and DNA Methylation | Lifetime | 997 | NL 23 | 97.87 |
| Gut microbiota and health | Lifetime | 666 | NL 25 | 97.85 |
| Mycobacterium research and diagnosis | Lifetime | 591 | NL 23 | 97.30 |
| Phagocytosis and Immune Regulation | Lifetime | 171 | NL 4 | 96.73 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 431 | NL 21 | 97.14 |
| Pneumonia and Respiratory Infections | Lifetime | 897 | NL 31 | 97.23 |
| Infectious Diseases and Mycology | Lifetime | 331 | NL 18 | 95.76 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 745 | NL 17 | 96.56 |
| Autophagy in Disease and Therapy | Lifetime | 823 | NL 7 | 95.46 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 572 | NL 27 | 95.82 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 705 | NL 41 | 95.90 |
| Adrenal Hormones and Disorders | Lifetime | 760 | NL 39 | 93.32 |
| NF-κB Signaling Pathways | Lifetime | 971 | NL 9 | 92.68 |
| Kawasaki Disease and Coronary Complications | Lifetime | 924 | NL 12 | 85.56 |
| Whipple's Disease and Interleukins | Lifetime | 470 | NL 9 | 67.87 |
| Romani and Gypsy Studies | Lifetime | 856 | NL 24 | 45.73 |
| Diabetes and associated disorders | 2021-2025 | 2 | NL 1 | 99.64 |
| COVID-19 Impact on Reproduction | 2021-2025 | 3 | NL 1 | 99.63 |
| Immune responses and vaccinations | 2021-2025 | 1 | NL 1 | 99.93 |
| Immune cells in cancer | 2021-2025 | 30 | NL 2 | 98.88 |
| COVID-19 Clinical Research Studies | 2021-2025 | 161 | NL 4 | 99.11 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 77 | NL 2 | 98.43 |
| Epigenetics and DNA Methylation | 2021-2025 | 151 | NL 2 | 96.85 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 371 | NL 8 | 98.40 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 51 | NL 3 | 98.23 |
| Immune Response and Inflammation | 2021-2025 | 85 | NL 7 | 94.04 |
| Long-Term Effects of COVID-19 | 2021-2025 | 529 | NL 6 | 95.35 |
| Sepsis Diagnosis and Treatment | 2021-2025 | 268 | NL 21 | 95.60 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 122 | NL 2 | 92.31 |
| Neonatal Respiratory Health Research | 2021-2025 | 607 | NL 27 | 93.34 |
| Inflammasome and immune disorders | 2021-2025 | 365 | NL 4 | 89.90 |
| Phagocytosis and Immune Regulation | 2021-2025 | 208 | NL 4 | 83.33 |
| Antifungal resistance and susceptibility | 2021-2025 | 688 | NL 17 | 87.77 |
| Fungal Infections and Studies | 2021-2025 | 678 | NL 20 | 84.71 |
| HIV-related health complications and treatments | 2021-2025 | 849 | NL 21 | 77.85 |
| Thermal Regulation in Medicine | 2021-2025 | 677 | NL 23 | 61.93 |
| Adrenal Hormones and Disorders | 2021-2025 | 891 | NL 25 | 64.94 |
| Inflammation biomarkers and pathways | 2021-2025 | 353 | NL 8 | 46.81 |
| Case Reports on Hematomas | 2021-2025 | 398 | NL 12 | 37.86 |
| Clusterin in disease pathology | 2021-2025 | 187 | NL 3 | 24.34 |